PARP inhibitors expand their role beyond BRCA mutations in first-line, newly diagnosed ovarian cancer
At yesterday’s Presidential Symposium, favourable results were presented from three phase III trials, which are likely to lead to a practice-changing role for PARP inhibitors in the treatment of newly diagnosed advanced ovarian cancer. PARP…
Read More